Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
View in:
PubMed
subject areas
Animals
Antibodies, Bispecific
Carcinoma, Non-Small-Cell Lung
Drug-Related Side Effects and Adverse Reactions
ErbB Receptors
Humans
Immune System Diseases
Lung Neoplasms
Pupa
authors with profiles
Ravi Salgia